<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970944</url>
  </required_header>
  <id_info>
    <org_study_id>H133A031713</org_study_id>
    <nct_id>NCT00970944</nct_id>
  </id_info>
  <brief_title>Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)</brief_title>
  <official_title>A Multicenter Prospective Randomized Controlled Trial of the Effectiveness of Amantadine Hydrochloride in Promoting Recovery of Function Following Severe Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JFK Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Department of Education</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>JFK Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a controlled trial of amantadine to improve level of function following severe
      traumatic brain injury.

      The purpose of this study is:

        1. To determine whether amantadine hydrochloride, given in a dose of 200-400 mg, improves
           functional recovery from the vegetative and minimally conscious states

        2. To determine whether amantadine-related gains in function persist following drug
           discontinuation

        3. To determine the safety profile of amantadine in patients with disorders of
           consciousness
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe traumatic brain injury may result in severe disorders of consciousness (DOC),
      including coma, the vegetative state (VS) and the minimally conscious state (MCS). The longer
      the duration of impaired consciousness, the worse the ultimate functional prognosis, with
      only about half of those individuals who remain unconscious for a month post-TBI regaining
      consciousness within a year. The severe functional disability associated with prolonged DOC
      places enormous emotional, financial, ethical, and logistical strains on caregivers and major
      resource demands on society. Numerous treatments have been recommended to hasten the return
      of consciousness or improve the ultimate level of recovery, including various psychotropic
      drugs, &quot;coma stimulation&quot; therapy and others. However, none of these treatments has proven
      efficacy in well-controlled research. The main obstacles to Class I evidence in this area
      have been the small samples of individuals with serious DOC in individual facilities, the
      variability of recovery trajectories within this heterogeneous population, and the reluctance
      to undertake placebo controlled trials.

      In the proposed study, 7 facilities (including two with TBI Model Systems designations) that
      participated in a multi-center research network called the Consciousness Consortium, join
      with four additional brain injury rehabilitation centers (two in the U.S. and two in Europe)
      and a Data Coordinating Center at Columbia University, to conduct a prospective double blind
      randomized controlled trial of amantadine hydrochloride. 184 patients who remain in VS or MCS
      4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine
      (200 - 400 mg/day) vs. placebo, followed by a 2-week washout period. The Disability Rating
      Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised
      (CRS-R) serving as a supplementary measure. We hypothesize superior recovery in the
      amantadine group and maintenance of that advantage after washout. We will also explore
      whether treatment response differs by time post-injury and by diagnosis (i.e., VS or MCS) at
      treatment onset, and whether specific outcomes of importance to caregivers are achieved more
      often in the amantadine group. We have developed plans for intensive education of caregivers
      and clinicians about this study to address perceived barriers to enrollment and will also use
      the information gathered during these interactions to develop consumer-oriented dissemination
      activities. Project outputs and findings will be disseminated to appropriate consumer and
      professional audiences using a variety of formats and will include: (1) improved family
      member understanding of DOC which will facilitate improved adjustment and caregiving and (2)
      clear guidance to clinicians regarding the effectiveness of amantadine for persons with DOC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disability Rating Scale: Functional Status</measure>
    <time_frame>Randomization and weekly for 6 weeks. The primary study endpoint was week 4 and drug washout was week 6.</time_frame>
    <description>Measure of function after traumatic brain injury (TBI) intended to measure function from &quot;coma to community.&quot; Minimum score= 0; Maximum score= 29 (High scores are indicative of greater degree of disability).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>JFK Coma Recovery Scale-Revised: Neurobehavioral Status</measure>
    <time_frame>Week 4 (primary endpoint); Week 6 (post-washout)</time_frame>
    <description>Measure of neurobehavioral function and clinical change for individuals with severe alterations of consciousness.
Minimum score= 0; Maximum score= 23 (Higher scores are indicative of a higher-level of neurobehavioral function).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Amantadine HCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine Hydrochloride</intervention_name>
    <description>184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.</description>
    <arm_group_label>Amantadine HCL</arm_group_label>
    <other_name>Symmetrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals between ages 16 and 65 with traumatic brain injury as defined by the TBI
             Model System syllabus (i.e., damage to brain tissue caused by an external mechanical
             force as evidenced by loss of consciousness or post-traumatic amnesia due to brain
             trauma, skull fracture, or objective neurological findings that can be reasonably
             attributed to TBI on physical or mental status examination).

          -  Individuals are at least 4 weeks but less than 16 weeks post-injury and have a
             Disability Rating Scale (DRS) score at enrollment of 12 or greater, and no consistent
             command following or functional communication (as defined by the JFK.

        Exclusion Criteria:

          -  Women who are pregnant,

          -  Individuals with missile-type penetrating brain injury,

          -  Premorbid major CNS/developmental abnormality (e.g., mental retardation, prior
             significant brain damage, etc.),

          -  History of more than 1 seizure (clinical or electrographic, but not including
             epileptiform or other irritative discharges) in the 4 weeks prior to enrollment
             (individuals with premorbid idiopathic epilepsy are eligible to enroll under two
             conditions: a) if their pre-injury seizure frequency was less than once/month and they
             have had no more than 1 seizure/month since injury and b) if a clear provocation was
             present that would otherwise disqualify a subject, the subject can be enrolled, since
             these events would not be considered idiopathic),

          -  Prior exposure to AH post-TBI,

          -  Unwillingness to discontinue or change confounding psychotropic drugs prior to
             enrollment, OR

          -  Allergy or medical contraindication to AH and significant impairment of renal function
             (as evidenced by a calculated creatinine clearance of &lt; 60 ml/min).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph T. Giacino, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Rehabilitation Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Whyte, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moss Rehabilitation Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Braintree Rehabilitation Hospital</name>
      <address>
        <city>Braintree</city>
        <state>Massachusetts</state>
        <zip>02184</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Rehabilitation Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnyview Rehabilitation Hospital</name>
      <address>
        <city>Schenectady</city>
        <state>New York</state>
        <zip>12308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Rehabilitation Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moss Rehabilitation Research Institute</name>
      <address>
        <city>Elkins Park</city>
        <state>Pennsylvania</state>
        <zip>19027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Rehabilitation Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Pennsylvania</state>
        <zip>19355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas NeuroRehabilitation Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK 2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik Bad Aibling</name>
      <address>
        <city>Bad Aibling</city>
        <zip>83043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Neresheim</name>
      <address>
        <city>Neresheim</city>
        <zip>73450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <results_first_submitted>December 12, 2011</results_first_submitted>
  <results_first_submitted_qc>September 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2012</results_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spaulding Rehabilitation Hospital</investigator_affiliation>
    <investigator_full_name>Joseph T Giacino</investigator_full_name>
    <investigator_title>Director of Rehabilitation Neuropsychology</investigator_title>
  </responsible_party>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Disorders of Consciousness</keyword>
  <keyword>Functional Outcome</keyword>
  <keyword>Amantadine Hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>February 23,2003 through March 15, 2010. Eleven rehabilitations centers in the USA (8) and Europe (3)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Amantadine HCL</title>
          <description>100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Visually identical compound administered in the same manner (ie enterally) as the actual study drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amantadine HCL</title>
          <description>100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Visually identical compound administered in the same manner (ie enterally) as the actual study drug.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="184"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="15.3"/>
                    <measurement group_id="B2" value="37.2" spread="15.4"/>
                    <measurement group_id="B3" value="36.4" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>JFK Coma Recovery Scale-Revised: Neurobehavioral Status</title>
        <description>Measure of neurobehavioral function and clinical change for individuals with severe alterations of consciousness.
Minimum score= 0; Maximum score= 23 (Higher scores are indicative of a higher-level of neurobehavioral function).</description>
        <time_frame>Week 4 (primary endpoint); Week 6 (post-washout)</time_frame>
        <population>Analyses were conducted according to the ITT principle so that all 184 patients randomized were included for analysis. Imputation techniques were not undertaken since missing data were infrequent and unrelated to study outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Amantadine</title>
            <description>Amantadine (200-400 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Visually identical compound administered in the same manner (ie enterally) as the study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>JFK Coma Recovery Scale-Revised: Neurobehavioral Status</title>
          <description>Measure of neurobehavioral function and clinical change for individuals with severe alterations of consciousness.
Minimum score= 0; Maximum score= 23 (Higher scores are indicative of a higher-level of neurobehavioral function).</description>
          <population>Analyses were conducted according to the ITT principle so that all 184 patients randomized were included for analysis. Imputation techniques were not undertaken since missing data were infrequent and unrelated to study outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (Primary endpoint)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="6.1"/>
                    <measurement group_id="O2" value="14.2" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Post-washout)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="6.3"/>
                    <measurement group_id="O2" value="15.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We will have 80% power to detect a one point difference in DRS score between the groups across the four week treatment window. With this sample size, we will be able to detect any unforeseen adverse events that have a prevalence of at least 2.5% in each group with 90% probability. With 92 patients per group we will be able to estimate the rate of adverse events to within Â±10%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disability Rating Scale: Functional Status</title>
        <description>Measure of function after traumatic brain injury (TBI) intended to measure function from &quot;coma to community.&quot; Minimum score= 0; Maximum score= 29 (High scores are indicative of greater degree of disability).</description>
        <time_frame>Randomization and weekly for 6 weeks. The primary study endpoint was week 4 and drug washout was week 6.</time_frame>
        <population>Analyses were conducted according to the intention-to-treat principle. 184 subjects were randomized and included for analysis. Since missing data were infrequent and unrelated to the study outcome, imputation methods were not undertaken.</population>
        <group_list>
          <group group_id="O1">
            <title>Amantadine</title>
            <description>Amantadine (200-400 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Visually identical compound administered in the same manner (ie enterally) as the actual study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Disability Rating Scale: Functional Status</title>
          <description>Measure of function after traumatic brain injury (TBI) intended to measure function from &quot;coma to community.&quot; Minimum score= 0; Maximum score= 29 (High scores are indicative of greater degree of disability).</description>
          <population>Analyses were conducted according to the intention-to-treat principle. 184 subjects were randomized and included for analysis. Since missing data were infrequent and unrelated to the study outcome, imputation methods were not undertaken.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (Primary endpoint)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="4.7"/>
                    <measurement group_id="O2" value="18.7" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Drug washout)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="5.2"/>
                    <measurement group_id="O2" value="17.8" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The planned sample size of 184 patients provided 80% power to detect a difference between the AH and placebo in the rate of Disability Rating Scale (DRS) score change of 0.3 points/week (1.22 DRS point mean difference by the end of the 4-week treatment interval). Two blinded interim analyses were conducted at 60 and 120 patients recruited using the O'Brien-Fleming boundary, with alpha levels of 0.0005 and 0.014. The final analysis used an alpha level of 0.045.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>The final analysis used a significance level of 0.045.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Final analysis adjusted for early v. late enrollment relative to date of injury, baseline CRS-R rating category (MCS vs. VS), and site.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.088</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Amantadine HCL</title>
          <description>100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Visually identical compound administered in the same manner (ie enterally) as the actual study drug.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Other Abnormal Laboratory</sub_title>
                <description>Anemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other Gastrointestinal Problems</sub_title>
                <description>GI bleeding, gastritis, bowel obstruction, colon carcinoma, peritonitis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Medical Problems</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Intracranial Hemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Other Neurologic</sub_title>
                <description>Bilateral subdural fluid collection, arm and head tremor</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Autonomic Storm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoarousal/Lethargy/Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia / Sleep Disturbance</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>General Medical Problems</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <description>Does not include urinary tract infection</description>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonia / Spasticity</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation / Aggression</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="87"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph T Giacino, PhD</name_or_title>
      <organization>Spaulding Rehabilitation Hospital</organization>
      <phone>617-573-2757</phone>
      <email>jgiacino@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

